Loading...
Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunction
Immunotherapy has changed the pattern of treatment in cancer. The interaction between programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibits the activation of T cells, and PD-1/PD-L1 inhibitors can increase the immune response to cancer cells by inducing the immune cells, which has...
Saved in:
| Published in: | Ann Transl Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
AME Publishing Company
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7396795/ https://ncbi.nlm.nih.gov/pubmed/32793733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-4980 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|